Asep Medical Confirms AI for Better Biofilm Infections


In a recent presentation at the US Biophysical Society in Philadelphia, Dr. Bob Hancock, CEO of Asep Medical Holdings Inc., shared how the innovative use of artificial intelligence (AI) has led to the creation of new and improved treatments for biofilm infections.

Biofilms are bacterial communities that cause 65% of infections and are extremely difficult to treat. Asep Medical's peptides have shown strong activity against biofilms, offering a potential alternative to current treatments. By utilizing neural network AI methods, the company has been able to predict peptides with higher activity against biofilms, enhancing their ability to combat inflammation and explore various markets impacted by biofilms.

One of Asep's upcoming products is an oral irrigant/rinse designed to prevent biofilm infections in the oral cavity, which can lead to dental issues. Additionally, AI technology is being used in the development of the SepsetER blood-based gene expression test, which is undergoing regulatory approval studies in the USA. This test, developed at the University of British Columbia, analyzes immune responses to help improve diagnosis and treatment.

Comments

Popular posts from this blog

Scope, Inc. Partners With Gimmi® For Medical Device Distribution In North America

BIGO Ads: Game-Changing Solutions at GDC 2024

Sagard Opens First Gulf Office, Welcomes Regional Leader